Novozymes A/S EBIT

The latest EBIT for NVZMF is $900M as of June 2026. That compares with $-32M in the prior-year period — up 2950.4% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Novozymes A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVZMF's EBIT moved from $-32M to $900M — a 2950.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novozymes A/S's operating scale or balance-sheet position.

Against its sector companies, NVZMF currently prints $900M for EBIT, while the sector average sits near $2.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Novozymes A/S's growth, margins, and balance sheet.

A EBIT figure of $900M for NVZMF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting NVZMF's EBIT ($900M), review year-over-year change from $-32M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.